Ascend Wellness Charts Course as Medical Cannabis Enters New Federal Era

NEW YORK, NY – June 30, 2026 – In a move signaling a tectonic shift in the U.S. cannabis industry, Ascend Wellness Holdings, Inc. (AWH) announced today it has filed applications with the Drug Enforcement Administration (DEA) to register its state-licensed medical cannabis operations. The action makes AWH an early adopter in navigating a new federal landscape, leveraging an expedited pathway created by the historic rescheduling of medical marijuana to Schedule III of the Controlled Substances Act.

The filing represents a calculated step toward federal normalization for an industry long-caged by conflicting state and federal laws. "This is an important first step for medical cannabis patients and the medical community, while laying the groundwork for broader normalization across the industry," said Sam Brill, CEO & Director of AWH, in a statement. Brill expressed optimism about future reforms, including a DEA hearing on adult-use cannabis, which could "align the industry with more economic opportunities and regulatory frameworks available to traditional businesses."

The Regulatory Maze: Navigating Schedule III

AWH's proactive filing is a direct response to the DEA's final order, effective April 28, 2026, which officially moved state-licensed medical marijuana from the highly restrictive Schedule I category to Schedule III. This reclassification acknowledges cannabis's accepted medical use and lower potential for abuse, placing it in the same category as substances like ketamine and anabolic steroids.

To manage this transition, the DEA established an expedited registration pathway for existing state-licensed medical cannabis businesses. Companies that file within a 60-day window can continue operating under their state licenses while their federal applications are under review, a process the DEA has committed to completing within six months. For companies like AWH, meeting this deadline is not just strategic, but essential. Operating a business that handles Schedule III substances without DEA registration is a federal violation, making these filings a critical compliance hurdle.

The new process requires applicants to provide proof of a valid state license, detailed information on criminal histories, and lists of personnel with access to the controlled substances. The associated fees—ranging from $794 for a dispensary to $3,699 for a manufacturer—are a small price to pay for entry into this new federally-recognized system.

The Billion-Dollar Question: Unlocking Economic Opportunity

The most immediate and profound impact of Schedule III status is the liberation from Section 280E of the Internal Revenue Code. For decades, this punitive tax provision has prohibited cannabis businesses from deducting standard operating expenses—like rent, payroll, and marketing—because they were trafficking in a Schedule I substance. This resulted in effective tax rates that could exceed 70%, crippling cash flow and hindering growth.

With medical cannabis operations now exempt from 280E, the financial relief will be immense. Industry analysts project that the change could inject an additional $1.6 to $2.2 billion in after-tax cash flow into the industry annually. For a typical dispensary, this could mean an annual federal tax savings of around $268,000, with larger, high-volume stores potentially saving closer to $800,000 per year.

However, the road to financial normalization is not without its complexities. This tax relief applies only to qualifying medical cannabis activities. Vertically integrated operators like AWH, which serve both medical and adult-use markets, will face the intricate task of segregating expenses and revenue streams to remain compliant. Furthermore, while the move is a step in the right direction, it does not automatically resolve the industry's banking crisis. Full access to traditional financial services will likely require the passage of separate legislation, such as the long-stalled SAFER Banking Act.

Ascend's Strategic Gambit

For Ascend Wellness Holdings, this filing is more than a compliance measure; it's a strategic imperative. The company, which operates 51 retail locations and six cultivation facilities across seven states, reported a net loss of $29.5 million in the first quarter of 2026. While an improvement from the previous quarter, AWH carries a net debt of $241.2 million, including $300 million in senior secured notes at a steep 12.75% interest rate. The potential tax savings from 280E relief are therefore not just a bonus, but a critical lifeline that could drastically improve its path to sustained profitability.

By being among the first multi-state operators (MSOs) to publicly announce its DEA filings, AWH positions itself as a leader in operational readiness and regulatory acumen. In a fiercely competitive market against giants like Green Thumb Industries and Curaleaf, demonstrating the ability to navigate complex federal oversight provides a significant advantage. This proactive stance may enhance credibility with institutional investors and lenders, who have remained on the sidelines due to federal illegality. It sets a precedent for the industry, establishing a blueprint for how to transition from a state-based patchwork to a federally regulated system.

A New Era for Patients and Practitioners

Beyond the balance sheets and stock tickers, the shift to Schedule III promises the most significant impact for patients. The federal government's acknowledgment of cannabis's medical value is a monumental step in reducing the stigma that has long surrounded its use. This could encourage more states to adopt medical programs and embolden healthcare providers to educate themselves and their patients on its therapeutic potential.

The reclassification also dismantles significant barriers to research. Scientists will now have an easier time securing materials and funding for clinical trials, accelerating the development of FDA-approved cannabis-based medicines and providing a deeper understanding of dosing, safety, and efficacy. This will ultimately lead to safer, more reliable products and better-informed medical guidance.

While Schedule III status does not mandate insurance coverage, it opens the door for greater integration into mainstream healthcare. Physicians will be able to discuss and potentially prescribe medical cannabis with less legal ambiguity, and pharmacists may eventually be permitted to dispense these products, dramatically improving patient access and care coordination. The legal storm cloud that has hung over medical professionals discussing cannabis is beginning to dissipate, replaced by a new, albeit complex, landscape of federally recognized medical use.